01 Shift from Traditional Large-Scale Trials Towards Advanced, Adaptive Trial Designs for Rare Diseases The cell and gene therapy (CGT) clinical trial landscape is witnessing a shift from conventional, large-scale randomized controlled trials to more adaptive, patient-centric designs tailored for small and rare disease populations. Recently, the U.S. Food and Drug Administration (FDA) released a draft guidance titled “Innovative Designs for Clinical Trials of Cellular and Gene Therapy Products in Small Populations”, encouraging the use of flexible methodologies such as single-arm studies, Bayesian models, and externally controlled trials. This transition aimed to accelerate therapy development while maintaining data integrity and patient safety. Such a transformative shift supported faster approvals and more inclusive participation in rare disease trials, marking a crucial evolution in the CGT clinical research framework.
02 Transition Towards Allogeneic “Off-the-Shelf” and Commercially Viable Platforms from Autologous Cell Therapies The movement from personalized autologous therapies, which require cells derived from each individual patient, to allogeneic “off-the-shelf” therapies that use donor-derived cells for standardized production and broader clinical accessibility, enhances the market growth. Recently, Longeveron Inc. announced positive Phase 2a results for laromestrocel, an allogeneic cell therapy for mild Alzheimer’s disease, and reported a Type B meeting with the FDA alongside RMAT and Fast Track designations. This reflected the industry’s strategic shift toward therapies that can be produced, stored, and delivered more efficiently, enhancing their commercial viability and patient reach.
June 2026 Thermo Fisher Scientific expanded its global cell therapy manufacturing and clinical development services by opening additional GMP capabilities to accelerate cell and gene therapy clinical trials.
April 2026 IQVIA and NVIDIA expanded their collaboration to integrate AI-driven technologies into clinical trial design and execution, enhancing efficiency for advanced therapies including cell and gene therapies.
January 2026 Charles River Laboratories expanded its cell and gene therapy testing and manufacturing support services to strengthen end-to-end clinical trial capabilities for biopharmaceutical developers.
September 2025 Labcorp launched expanded central laboratory and biomarker testing services specifically designed to support global cell and gene therapy clinical trials from early to late-stage development.
June 2025 Thermo Fisher Scientific expanded its viral vector manufacturing capacity through new facility investments, supporting increasing demand for cell and gene therapy clinical development programs.